Heparin/Leo

Heparin/Leo is an injectable solution containing the anticoagulant heparin sodium. It is supplied as a sterile liquid for intravenous use and is marketed in the European Union by prescription only. Heparin/Leo enhances antithrombin III activity, inhibiting thrombin and factor Xa, which helps prevent abnormal clot formation in clinical settings such as surgery or dialysis. It may be administered under controlled dosing protocols in hospitals and specialized care facilities.

Heparin/Leo is indicated for several antithrombotic purposes in clinical practice.

- Prevention and treatment of venous thromboembolism (deep‑vein thrombosis and pulmonary embolism). - Prophylaxis of clot formation during cardiac surgery, cardiopulmonary bypass, or other invasive procedures. - Anticoagulation for patients undergoing hemodialysis or continuous renal replacement therapy. - Management of acute coronary syndromes, including unstable angina and non‑ST‑segment elevation myocardial infarction. - Use in obstetric settings to prevent thrombosis in high‑risk pregnant patients when clinically justified.

Adverse reactions to Heparin/Leo vary in frequency and severity.

Common: - Minor bleeding at injection site or bruising. - Mild thrombocytopenia (decrease in platelet count). - Nausea or transient headache. - Elevated liver enzymes (asymptomatic).

Serious: - Major hemorrhage, including internal bleeding. - Heparin‑induced thrombocytopenia (HIT) with risk of thrombosis. - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Spontaneous spinal or epidural hematoma.

Clinicians should consider several precautions before prescribing Heparin/Leo.

- Assess baseline coagulation parameters and platelet count. - Use caution in patients with active bleeding, recent surgery, or trauma. - Adjust dose in renal impairment or elderly patients. - Monitor for signs of heparin‑induced thrombocytopenia during therapy. - Avoid use in individuals with known hypersensitivity to heparin or its additives. - Consider pregnancy status; benefits must outweigh potential risks. - Review concomitant use of other anticoagulants or antiplatelet agents.

Heparin/Leo may interact with other medications that affect hemostasis or drug metabolism.

Avoid: - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without close monitoring. - Simultaneous administration of thrombolytic agents (e.g., alteplase) due to heightened bleeding risk.

Use with caution: - Antiplatelet drugs such as aspirin, clopidogrel, or NSAIDs may increase bleeding tendency. - Certain antibiotics (e.g., vancomycin) and antifungals can potentiate anticoagulant effect. - High‑dose corticosteroids may affect platelet function. - Intravenous immunoglobulin therapy may interfere with heparin activity.